Protagonist therapeutics announces oral and poster presentations on rusfertide at the 67th annual ash meeting

Newark, california / access newswire / november 3, 2025 / protagonist therapeutics, inc. ("protagonist" or the "company") announced that clinical data on rusfertide in polycythemia vera, including the phase 3 verify study, will be the focus of four presentations at the 67th annual american society of hematology (ash) annual meeting being held in orlando, florida, from december 6-9, 2025. ash presentation details: presenting author: andrew kuykendall, md (moffitt cancer center) publication number: 81 title: rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: durability of response and safety results through week 52 from the randomized controlled phase 3 verify study oral session name: 634.
ASH Ratings Summary
ASH Quant Ranking